Article
NeurologyLive Friday 5 — April 24, 2020
Author(s):
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Reena Mehra, MD, MS: Expediting Telemedicine During COVID-19
The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her insight on how telemedicine is being utilized to help diagnose and treat sleep disorders amidst COVID-19.
2: Siponimod Shows Long-Term Benefit for Secondary Progressive MS
Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.
3: Robert E. Shapiro, MD, PhD: Takeaways From Migraine Telemedicine
The professor of neurology at the University of Vermont Larner College of Medicine detailed what lessons and highlights he’s learned from shifting his migraine care to a telemedicine-based model during the COVID-19 pandemic.
4: Postpartum Relapses Similar to Pre-Pregnancy Rates for Women With MS
Exclusive breastfeeding may be recommended after it was shown to reduce the risk of postpartum relapses.
5: Solriamfetol: Recently FDA Approved for Narcolepsy
Expert sleep specialists discuss solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy, including its novel mechanism of action as a dual-acting dopamine and norepinephrine reuptake inhibitor.
